Financial Performance - Fiscal year 2025 Q2 revenue was 295thousand,primarilyfromactivitiessupportingtheU.S.DepartmentofHomelandSecurity[4]−Thecompanyreportedanetlossof4,009 thousand for the three months ended December 31, 2024, compared to a net loss of 2,641thousandforthesameperiodin2023[9]−Astrotech′sgrossprofitforQ22025was164 thousand, compared to 532thousandinQ22024[9]−Thecompany’soperatingexpensesforQ22025were4,476 thousand, an increase from 3,600thousandinQ22024[9]−Researchanddevelopmentexpensesincreasedto2,437 thousand in Q2 2025 from 1,578thousandinQ22024[9]−Astrotech′saccumulateddeficitreached244,307 thousand as of December 31, 2024[10] Assets and Investments - Astrotech's cash and cash equivalents and liquid investments totaled 24.7million,supportingresearchanddevelopmentandpotentialacquisitions[4]−Astrotech′sconsolidatedbalancesheetshowstotalassetsof31,001 thousand as of December 31, 2024[10] Product Development - The company introduced the TRACER NTD narcotics trace detector, capable of accurately identifying fentanyl and other drugs[3] - The company received a purchase order for TRACER 1000 explosive trace detectors from Intuitive Research and Technology Corporation[4]